Aarti Pharmalabs Limited (NSE:AARTIPHARM)

Market Cap	66.40B
Revenue (ttm)	20.57B
Net Income (ttm)	2.49B
Shares Out	90.63M
EPS (ttm)	27.50
PE Ratio	26.64
Forward PE	n/a
Dividend	3.50 (0.48%)
Ex-Dividend Date	Feb 14, 2025

Volume	220,037
Average Volume	673,560
Open	738.45
Previous Close	732.65
Day's Range	721.70 - 749.35
52-Week Range	399.55 - 837.25
Beta	-0.63
RSI	51.65
Earnings Date	May 12, 2025

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medication...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,095
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In 2023, Aarti Pharmalabs's revenue was 18.53 billion, a decrease of -4.76% compared to the previous year's 19.45 billion. Earnings were 2.17 billion, an increase of 12.10%.